Other
Refractory
0
Pipeline Programs↗
56
Active Trials↗
31
Companies Involved↗
Refractory is an early-stage landscape with 0 programs across 31 companies. The most active players are Chongqing Precision Biotech Co., Ltd, Novartis, Hebei Senlang Biotechnology Inc., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
177
clinical trials
Completed56 · 32%
Unknown status35 · 20%
Recruiting34 · 19%
Terminated19 · 11%
Not yet recruiting15 · 8%
Withdrawn10 · 6%
Other8 · 5%
Clinical Trials
Trial Activity
177 trials
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06934447·18 enrolled
Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD
Recruiting·—·Phase 1·NCT06233110·30 enrolled
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06570447·22 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)